抑制BRAF通过增强tsMHCII介导的免疫识别使甲状腺癌对免疫治疗敏感
该研究探讨甲状腺乳头状癌(PTC)免疫逃逸机制,发现BRAFV600E突变通过TGF-β1/SMAD3通路下调肿瘤特异性MHCII(tsMHCII)表达,抑制CD4+ T细胞激活。在转基因小鼠模型中,BRAF抑制剂PLX4032联合抗PD-1抗体可增加CD4+ T细胞浸润并有效抑制肿瘤生长。
要点
- BRAFV600E突变与PTC中tsMHCII低表达相关
- BRAF组成性激活经TGF-β1/SMAD3下调tsMHCII导致免疫逃逸
- PLX4032联合抗PD-1抗体在临床前模型中协同抑制肿瘤
核心结论
- BRAFV600E突变通过TGF-β1/SMAD3通路下调tsMHCII表达,增强PTC免疫逃逸。
- PLX4032联合抗PD-1抗体在临床前小鼠模型中促进免疫系统识别和消除PTC。
研究设计与样本
- 采用iTRAQ蛋白质组学分析伴或不伴BRAFV600E突变的PTC样本中差异表达蛋白。
- 通过体外调控BRAF/MAPK及相关通路研究肿瘤细胞逃逸的分子机制。
- 在自发性甲状腺癌转基因小鼠模型中评估tsMHCII的病理意义及靶向免疫治疗。
主要发现
- 蛋白质组学显示tsMHCII水平在BRAFV600E相关PTC中显著降低,且与BRAF突变状态负相关。
- BRAF组成性激活降低肿瘤细胞表面tsMHCII表达,抑制CD4+ T细胞激活并导致免疫逃逸。
- 通路分析表明TGF-β1/SMAD3介导tsMHCII抑制,BRAF抑制(BRAFi)可逆转该抑制。
- PLX4032联合抗PD-1抗体通过增加CD4+ T细胞浸润有效阻断转基因PTC小鼠模型中的肿瘤生长。
临床怎么用
- 对于晚期PTC患者,BRAF抑制剂联合抗PD-1抗体可能是一种有效的治疗策略。
- BRAFV600E突变状态可能提示tsMHCII低表达和免疫逃逸倾向,需进一步临床验证。
局限性
- 主要结论基于临床前转基因小鼠模型,尚需临床研究验证。
- 未报告人体临床试验数据及具体疗效数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Multiple mechanisms play roles in restricting the ability of T-cells to recognize and eliminate tumor cells. OBJECTIVE: To identify immune escape mechanisms involved in papillary thyroid carcinoma (PTC) to optimize immunotherapy. SETTING AND DESIGN: iTRAQ analysis was conducted to identify proteins differentially expressed in PTC samples with or without BRAFV600E mutation. Molecular mechanisms regulating tumor cell evasion were investigated by in vitro modulations of BRAF/MAPK and related pathways. The pathological significance of identified tumor-specific major histocompatibility complex class II (tsMHCII) molecules in mediating tumor cell immune escape and targeted immune therapy was further evaluated in a transgenic mouse model of spontaneous thyroid cancer. RESULTS: Proteomic analysis showed that tsMHCII level was significantly lower in BRAFV600E-associated PTCs and negatively correlated with BRAF mutation status. Constitutive activation of BRAF decreased tsMHCII surface expression on tumor cells, which inhibited activation of CD4+ T-cells and led to immune escape. Pathway analysis indicated that the transforming growth factor (TGF)-β1/SMAD3-mediated repression of tsMHCII, which could be reversed by BRAF inhibition (BRAFi). Targeting this pathway with a combined therapy of BRAF inhibitor PLX4032 and anti-PD-1 antibody efficiently blocked tumor growth by increasing CD4+ T-cell infiltration in a transgenic PTC mouse model. CONCLUSIONS: Our results suggest that BRAFV600E mutation in PTC impairs the expression of tsMHCII through the TGF-β1/SMAD3 pathway to enhance immune escape. Combined treatment with PLX4032 and anti-PD-1 antibody promotes recognition and elimination of PTC by the immune system in a pre-clinical mouse model, and therefore offers an effective therapeutic strategy for patients with advanced PTC.
引用
- Zhi J, Zhang P, Zhang W, et al. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition. J Clin Endocrinol Metab. 2021. PMID: 32936899. doi:10.1210/clinem/dgaa656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。